Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M0KB
|
||||
| Former ID |
DIB016445
|
||||
| Drug Name |
MK-6592
|
||||
| Synonyms |
VX-667
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Discontinued in Phase 1 | [1] | ||
| Company |
Vertex Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Aurora protein kinase | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Oocyte meiosis | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | ||||
| Separation of Sister Chromatids | |||||
| Resolution of Sister Chromatid Cohesion | |||||
| RHO GTPases Activate Formins | |||||
| WikiPathways | EGF/EGFR Signaling Pathway | ||||
| JAK/STAT | |||||
| Gastric Cancer Network 1 | |||||
| Integrated Breast Cancer Pathway | |||||
| APC/C-mediated degradation of cell cycle proteins | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024789) | ||||
| REF 2 | Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009 Aug;14(8):780-93. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.